THE EFFECTS OF FREEZING ON EPINEPHRINE AUTO-INJECTOR DEVICE FUNCTION

Orientation affects the integrity of glass ampoules of 1 in 1000 adrenaline on exposure to very low temperatures

In very cold environments, it may be burdensome or impossible for the polar medic to prevent medicines from freezing. We sought to investigate whether orientation affected the risk that glass ampoules of 1 in 1000 adrenaline, an important emergency drug, would break during freezing and subsequent thawing. Ampoules of adrenaline were orientated either upright, horizontally or inverted. They were exposed to freezing temperatures (-25°C or -80°C) and then allowed to thaw. A crossover design was used whereby the orientation of unbroken ampoules was changed for the next trial. No ampoules broke when frozen at -25°C and then thawed. When this was repeated at -80°C, ampoules reliably broke unless they were upright with no liquid in the top part of the ampoule. Upright orientation prevents the breakage of glass ampoules of 1 in 1000 adrenaline rapidly frozen at -80°C. The polar medic may consider storing ampoules upright if they are to be exposed to very low temperatures.

Repeated freezing to very low temperatures does not impact the amount ejected from EpiPen® and Jext® adrenaline autoinjectors

It has previously been shown that EpiPen® autoinjectors are likely to activate normally following up to five excursions to -25°C but data about the post-freezing performance of other brands of adrenaline autoinjectors has not previously been published. Additionally, conditions experienced by polar medics may be substantially colder than this and the performance of adrenaline autoinjectors following more extreme freeze-thaw cycles remains uncharacterised. Investigators in Antarctica and the United Kingdom performed laboratory testing on two brands of adrenaline autoinjector, EpiPen® and Jext® (12 devices of each type). A single freeze-thaw cycle involved freezing the device to -80°C then allowing it to come to room temperature. Devices were exposed to 0, 1, 5 or 15 freeze-thaw cycles. The mass of liquid ejected from each device, when activated, was then measured. No significant differences in the mass of the liquid ejected was found between the test groups. Multiple freeze-thaw cycles to -80°C are unlikely to significantly impact the amount of adrenaline solution expelled from EpiPen® and EpiPen® autoinjectors. This preliminary finding encourages further work investigating the safety and effectiveness of adrenaline autoinjectors after exposure to very low temperatures. This information would be valuable for future polar medics planning and delivering medical provision in extreme environments.

Wilderness Medical Society Clinical Practice Guidelines on Anaphylaxis

The Wilderness Medical Society convened a panel to review the literature and develop evidence-based clinical practice guidelines on the treatment of anaphylaxis, with an emphasis on a field-based perspective. The review also included literature regarding the definition, epidemiology, clinical manifestations, and prevention of anaphylaxis. The increasing prevalence of food allergies in the United States raises concern for a corresponding rise in the incidence of anaphylaxis. Intramuscular epinephrine is the primary treatment for anaphylaxis and should be administered before adjunctive treatments such as antihistamines, corticosteroids, and inhaled β agonists. For outdoor schools and organizations, selecting a method to administer epinephrine in the field is based on considerations of cost, safety, and first responder training, as well as federal guidelines and state-specific laws.